Treatment of Hemorrhagic Fever With Ribavirin

Hemorrhagic Fever Clinical Trial

Official title: Treatment Protocol for Adults With Hemorrhagic Fever With Renal Syndrome (HFRS) With Intravenous (IV) Ribavirin

Status Not yet recruiting

Clinical Trial Summary

Multisite protocol to provide IV Ribavirin treatment to patients with probable or suspected case of Hemorrhagic Fever with Renal Syndrome (HFRS)

Clinical Trial Description

This protocol is an open-label, single-arm, multisite protocol to provide IV ribavirin treatment to patients with probable or suspected case of HFRS. Individuals with a tentative diagnosis of HFRS will be admitted to the MTF and treated for up to 7 days with doses of IV ribavirin. ;

Related Conditions & MeSH terms

• Fever
• Hemorrhagic Fever

• NCT number: NCT04283513
• Study type: Interventional
• Source: U.S. Army Medical Research and Development Command
• Contact: Janice M Rusnak, M.D.
• Phone: 301-619-8447
• Email: janice.m.rusnak.ctr@mail.mil
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: October 31, 2022
• Completion date: July 2023